HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
62 hedge funds and large institutions have $156M invested in HOOKIPA Pharma in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
41% more capital invested
Capital invested by funds: $111M → $156M (+$45.4M)
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
17% more funds holding
Funds holding: 53 → 62 (+9)
0.6% more ownership
Funds ownership: 3.87% → 4.47% (+0.6%)
71% less call options, than puts
Call options by funds: $533K | Put options by funds: $1.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$10.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$8.21M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.12M |
| 4 |
Goldman Sachs
New York
|
+$1.87M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.22M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$2.51M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.44M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$998K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$522K |
HOOK Hedge Fund Activity: Q1 2021 in Review
62 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q1 2021, worth a combined $156M — up 41% from $111M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new HOOK positions and 8 closed out — a net gain of 9 holders — while 18 added to existing stakes and 14 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $10.9M. The largest seller was Artal Group, cutting an estimated $4.22M.
- 62 institutional investors held HOOKIPA Pharma (HOOK) as of Q1 2021, up from 53 in Q4 2020.
- Funds reported $156M of HOOKIPA Pharma stock for Q1 2021, up 41% quarter-over-quarter.
- 17 funds opened new HOOKIPA Pharma positions in Q1 2021 and 8 closed out, a net change of +9 holders.
- The largest HOOKIPA Pharma buyer in Q1 2021 was Nantahala Capital Management, an estimated $10.9M added.
- The largest HOOKIPA Pharma seller in Q1 2021 was Artal Group, an estimated $4.22M sold.
Based on aggregated 13F filings for Q1 2021.